Alfatide II | ligand |18F-Alfatide II | PET/CT | Breast Cancer

MedKoo Cat#: 125677 | Name: Alfatide II

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alfatide II is ligand for making 18F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study. 18F-alfatide II has been proven to have excellent clinical translational potential.

Chemical Structure

Alfatide II

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 125677

Name: Alfatide II

CAS#: N/A

Chemical Formula: C87H128N24O28S

Exact Mass: 1988.9100

Molecular Weight: 1990.18

Elemental Analysis: C, 52.51; H, 6.48; N, 16.89; O, 22.51; S, 1.61

Price and Availability

Size	Price	Availability
10mg	USD 1,250.00	2 Weeks
50mg	USD 2,050.00	2 Weeks
100mg	USD 3,850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Alfatide II; Alfatide-II; AlfatideII

IUPAC/Chemical Name

2,2',2''-(2-(4-(3-(13-((4-((2S,5S,11S,14R)-11-(carboxymethyl)-5-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)butyl)carbamoyl)-21-((2S,5S,11S,14R)-11-(carboxymethyl)-5-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)-11,16-dioxo-3,6,9-trioxa-12,17-diazahenicosyl)thioureido)benzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid

InChi Key

YNIMRGCHOCEKOJ-PDHQBNHTSA-N

InChi Code

InChI=1S/C87H128N24O28S/c88-85(89)94-27-5-9-58-77(129)97-44-68(115)101-65(42-71(118)119)83(135)107-63(40-52-13-19-56(112)20-14-52)81(133)105-60(79(131)103-58)7-1-3-25-92-67(114)24-23-62(100-70(117)50-139-38-37-138-36-35-137-34-29-96-87(140)99-54-17-11-51(12-18-54)39-55-46-110(48-74(124)125)31-30-109(47-73(122)123)32-33-111(55)49-75(126)127)76(128)93-26-4-2-8-61-80(132)104-59(10-6-28-95-86(90)91)78(130)98-45-69(116)102-66(43-72(120)121)84(136)108-64(82(134)106-61)41-53-15-21-57(113)22-16-53/h11-22,55,58-66,112-113H,1-10,23-50H2,(H,92,114)(H,93,128)(H,97,129)(H,98,130)(H,100,117)(H,101,115)(H,102,116)(H,103,131)(H,104,132)(H,105,133)(H,106,134)(H,107,135)(H,108,136)(H,118,119)(H,120,121)(H,122,123)(H,124,125)(H,126,127)(H4,88,89,94)(H4,90,91,95)(H2,96,99,140)/t55?,58-,59-,60-,61-,62?,63+,64+,65-,66-/m0/s1

SMILES Code

O=C(NCCCC[C@H]1C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@H](CC2=CC=C(O)C=C2)C(N1)=O)=O)=O)=O)=O)C(NC(COCCOCCOCCNC(NC3=CC=C(CC4CN(CC(O)=O)CCN(CC(O)=O)CCN4CC(O)=O)C=C3)=S)=O)CCC(NCCCC[C@H]5C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@H](CC6=CC=C(O)C=C6)C(N5)=O)=O)=O)=O)=O)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,990.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wu J, Wang S, Zhang X, Teng Z, Wang J, Yung BC, Niu G, Zhu H, Lu G, Chen X. ¹⁸F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study. J Nucl Med. 2018 Dec;59(12):1809-1816. doi: 10.2967/jnumed.118.208637. Epub 2018 Apr 26. PMID: 29700127; PMCID: PMC6910641. 2: Wu J, Tian J, Zhang Y, Ji H, Sun J, Wang X, Sun C, Wang L, Teng Z, Lu G, Zhu H, Chen X. ¹⁸F-Alfatide II for the evaluation of axillary lymph nodes in breast cancer patients: comparison with ¹⁸F-FDG. Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2869-2876. doi: 10.1007/s00259-021-05333-z. Epub 2022 Feb 9. PMID: 35138445. 3: Yu C, Pan D, Mi B, Xu Y, Lang L, Niu G, Yang M, Wan W, Chen X. (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2021-8. doi: 10.1007/s00259-015-3118-2. Epub 2015 Jul 1. PMID: 26121930; PMCID: PMC4626365. 4: Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X. Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases. Theranostics. 2015 Jul 12;5(10):1115-21. doi: 10.7150/thno.12938. PMID: 26199649; PMCID: PMC4508500. 5: Wu J, Zhang X, Jia Z, Zhou X, Qi R, Ji H, Sun J, Sun C, Teng Z, Lu G, Chen X. Combined ¹⁸F-FDG and ¹⁸F-Alfatide II PET May Predict Luminal B (HER2 Negative) Subtype and Nonluminal Subtype of Invasive Breast Cancer. Mol Pharm. 2022 Sep 5;19(9):3405-3411. doi: 10.1021/acs.molpharmaceut.2c00547. Epub 2022 Aug 16. PMID: 35972444.